Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

Fig. 2

Elevation of CD58 expression in HCC patients and predicted poor prognosis. a Typical IHC pictures of CD58 in HCC patient tissues and surrounding non-tumor tissues. b The expression of the CD58 protein in pairs of HCC and comparable non-tumor tissues from 24 patients were examined by western blotting. c, d Kaplan Meier analysis of overall survival (c) and tumor-free survival (d) in 69 patients based on the level of CD58 expression. Define C > N as high CD58 expression and C ≤ N as low CD58 expression. e Different CD58 staining intensity scores in tumor tissue. Cell staining is classified as 0–3 (10 × original magnification). f, g Kaplan Meier analysis of overall survival (f) and tumor-free survival (g) in 69 patients based on the CD58 expression level in tumor tissues. An IHC score > 5 was considered as CD58-High expression, while others were CD58-Low expression

Back to article page